Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + BR in previously treated iNHL
NCT01732926Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Jan 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in Indolent Non-Hodgkin Lymphoma (INHL) comparing Rituximab + Bendamustine + Idelalisib with Rituximab + Bendamustine + Placebo (2 arms). Primary endpoint: Progression-free Survival. Started Jan 2013; status: terminated.
02
Drugs
idelalisib
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01732926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732926.